Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
$101.54
-$1.49(-2.61%)
At close: 4:00 PM EST
$101.54
-$1.49(-2.61%)
Day’s Range― - ―
52-Week Range$38.81 - $102.66
Previous CloseN/A
Volume846.89K
Average Volume (3M)8.37M
Market Cap
$19.27B
Enterprise Value$12.09B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Feb 24, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding189,765,820
10 Day Avg. Volume4,019,659
30 Day Avg. Volume8,367,315
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)4.31
Price to Sales (P/S)3.75
P/FCF Ratio138.84
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue3.92
Enterprise Value/Gross Profit5.82
Enterprise Value/Ebitda-16.08
Forecast
1Y Price Target
$98.94Price Target Upside-2.56% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$3.23B
Bulls Say, Bears Say
Bulls Say
Growth PotentialExact Sciences is expected to be accretive to Abbott's revenue growth and gross margins, contributing significantly to the diagnostics segment.
Market ExpansionAbbott plans to expand the total addressable market by $40B+ with EXAS, adding a whole new growth vertical to its business.
Strategic AcquisitionsThe acquisition by Abbott is the largest in diagnostics history and validates the progress of the precision oncology diagnostics field.
Bears Say
Competing Bid ChallengesThere is a low probability for a new competitive bid that would drive the price higher than the proposed deal.
Financial ConcernsExact Sciences is expected to be dilutive in '26 and '27, but Abbott plans to return back to double-digit EPS growth in 2027.
Stock Rating DowngradeThe analyst downgraded Exact Sciences to a HOLD rating due to the limited upside potential of less than 5% from the current share price to the $105 offer.
Exact Sciences News
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $38.81 and its highest was $102.66 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $19.27B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Feb 24, 2026 which is in 59 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Nov 03, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.061 by -$0.039.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Overvalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.08.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 189,765,820 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.061. Following the earnings report the stock price went up 3.897%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exact Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$98.94 (-2.56% Downside)
$98.94 (-2.56% Downside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.73%
12-Months-Change
Fundamentals
Return on Equity
-34.54%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Company Deck
EXAS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.View all EXAS earnings summariesEXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$98.94
▼(-2.56% Downside)
Technical Analysis
Ownership Overview
1.04% Insiders
39.69% Mutual Funds
34.06% Other Institutional Investors
11.90% Public Companies and Individual Investors